Department Of Neurology
Sarah O'Shea, MD
Dr. O'Shea sees patients with all movement disorders including Parkinson's disease, Huntington's disease, atypical parkinsonism, tremor, ataxia, chorea, and dystonia. She specializes in Deep Brain Stimulation (DBS) for movement disorders, including patient selection, evaluation, intra-operative assessments, and post-operative programming. She is also skilled in neurotoxin injections for movement disorders and spasticity.

Dr. O'Shea's research interests include investigating prodromal biomarkers of Parkinson's disease and the effects of neurotoxicant exposure on the development of neurodegenerative disease. She also leads several clinical trials for Parkinson's disease and Huntington's disease. Her research has previously been funded by the American Parkinson's Disease Association (APDA).

Dr. O'Shea is a member of the International Parkinson and Movement Disorder Society (MDS) and the American Academy of Neurology (AAN). She is a credentialed member of the Parkinson Study Group (PSG) and Huntington Study Group (HSG). She was also appointed to serve on the exam writing committee for the American Board of Psychiatry and Neurology (ABPN). Dr. Sarah O'Shea is an Assistant Professor of Neurology at the Columbia University Vagelos College of Physician and Surgeons. She obtained her medical doctorate at the University of Illinois. She completed her residency training and served as Chief Resident in Neurology at the University of Iowa Hospitals and Clinics. She then completed her fellowship training in Movement Disorders at Columbia University Medical Center and completed the Neuroepidemiology Training Program (NETP, Master of Science in Epidemiology) during training at Columbia University. Prior to joining the faculty at Columbia, Dr. O'Shea was an Assistant Professor of Neurology in the Division of Movement Disorders at Boston University School of Medicine.

Clinical Studies Managed By This Investigator:
Condition Study Title
Huntington's Disease SAGE HD-201
Parkinson's Disease Parkinson's Progression Markers Initiative (PPMI)